MENLO PARK, Calif.,
Jan. 15, 2016 /PRNewswire/ --
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical
company, announced today that research being presented at the 2016
Winter Clinical Dermatology Conference next week shows its unique
formulation of minocycline, known as BPX-01, may offer a
breakthrough in acne treatment because it may not result in
systemic toxicities commonly associated with current use of the
orally administered antibiotic.
Minocycline is the antibacterial and anti-inflammatory medicine
most commonly prescribed to treat acne. However it is typically
used orally because no one has found a way to produce an effective
minocycline-based topical medication. BPX-01 is the first and
only stable hydrophilic (non-oil-based) topical gel formulation
with fully solubilized minocycline that effectively delivers the
antibiotic to the source of the acne.
Results from a preclinical toxicology study demonstrate that
both systemic exposure and peak plasma concentrations of
minocycline are minimized by topical administration, which
eliminates the risk of unwanted side-effects associated with oral
minocycline, including diarrhea, nausea, and dizziness that can
discourage compliance.
Study findings will be presented Monday at the Winter Clinical
Dermatology Conference, being held in Koloa, Hawaii, Jan.
15-20.
"The topical administration of minocycline via BPX-01 delivers
the antibiotic to the specific layer of skin where acne develops,
but does not result in a significant concentration of the drug in
the system, suggesting that it may offer dermatologists a safer way
to treat the condition," said Kin F. Chan, Ph.D., executive vice
president of research and development at BioPharmX Corporation.
"The preclinical studies suggest that this targeted delivery of
minocycline virtually eliminates any risk of systemic side
effects."
Most topical acne medications available today use less effective
antibiotics than minocycline. However, many are lipophilic (oil
based), which means they cannot effectively deliver even the less
effective antibiotic to the epidermis and the pilosebaceous region
where acne develops.
The BioPharmX research also found that its hydrophilic BPX-01
formulation distributes evenly, is not sticky and does not occlude
or irritate the skin, an advantage in the treatment of acne.
The American Academy of Dermatology calls acne the "most common
skin condition in the United States," affecting 40 million to 50
million Americans at any given moment. The disease can cause
permanent scarring, low self-esteem, depression and anxiety.
About BioPharmX™ Corporation
BioPharmX Corporation
(NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical
company, which seeks to provide products through proprietary
platform technologies for prescription, over-the-counter ("OTC"),
and supplement applications in the health and wellness markets,
including dermatology and women's health. To learn more about
BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, or the Securities Act, and Section 21E of the Securities
Exchange Act of 1934, as amended, or the Exchange Act, which are
subject to the "safe harbor" created by those section.
This press release contains forward-looking statements about the
company's expectations, plans, intentions, and strategies,
including, but not limited to, statements regarding, including with
respect to: the success of the commercialization of VI2OLET iodine,
the effectiveness of BPX01, the timing with respect to filing an
IND and clinical trials for BPX-01, the release of key data for
BPX01, the release of key data and the successful completion of
multi-site IRB studies for BPX03 and the successful completion of
the private placement with Korea Investment Partners Overseas
Expansion Platform Fund. These forward-looking statements may be
identified by words such as "plan", "expect," "anticipate,"
"believe," or similar expressions that are intended to identify
such forward-looking statements. These forward-looking
statements involve risks and uncertainties, as well as assumptions,
which, if they do not fully materialize or prove incorrect, could
cause our results to differ materially from those expressed or
implied by such forward-looking statements. The risks and
uncertainties include those described in the company's filings with
the Securities and Exchange Commission. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements. The forward-looking
statements included in this news release are made only as of the
date hereof and the company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities law.
BioPharmX and Violet are registered trademarks of BioPharmX,
Inc.
Logo - http://photos.prnewswire.com/prnh/20150711/235327LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/study-shows-topical-biopharmx-formulation-treats-acne-while-minimizing-systemic-exposure-of-minocycline-300205006.html
SOURCE BioPharmX Corporation